Abstract: In neuronal systems, the health and activity of mitochondria and synapses are tightly coupled. For this reason, it has been postulated that mitochondrial abnormalities may, at least in part, drive neurodegeneration in conditions such as Alzheimer’s disease (AD). Mounting evidence from multiple Alzheimer’s disease cell and mouse models and postmortem brains suggest that loss of mitochondrial integrity may be a key factor that mediates synaptic loss. Therefore, the prevention or rescue of mitochondrial dysfunction may help delay or altogether prevent AD-associated neurodegeneration. Since mitochondrial health is heavily dependent on antioxidant defenses, researchers have begun to explore the use of mitochondria-targeted antioxidants as therapeutic tools to prevent neurodegenerative diseases. This review will highlight advances made using a model mitochondria-targeted antioxidant peptide, SS31, as a potential treatment for AD.

Keywords: Alzheimer’s; SS31; mitochondria; antioxidant
1. Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disorder in aged populations worldwide. AD is characterized by deficits in cognition and memory, as well as personality and behavior [1]. Amyloid plaques and neurofibrillary tangles are the pathological hallmarks of AD [1,2], but since they both occur late in pathogenesis, they are unlikely to represent the primary cause of AD symptoms. Additional processes that have been identified in the etiology of AD include neuro-inflammation, synaptic damage, and structural and functional abnormalities in mitochondria [3–10]. Synaptic loss represents the best correlate to loss of memory and cognitive decline [11–13]. The mechanisms by which synaptic loss occur are largely unknown in AD, and the influence of early pathogenic events, such as mitochondrial dysfunction, on synaptic loss has not been fully described. The purpose of this article is to highlight the latest developments in AD research, regarding mitochondrial dysfunction and synaptic degeneration, with a special emphasis on the protective effects of the mitochondria-targeted antioxidant SS31 in AD neurons.

2. Alzheimer’s Disease Etiology Involves Mitochondrial Dysfunction

The initial cause of AD neurodegeneration is thought to be the abnormal processing of the amyloid beta (Aβ) precursor protein (AβPP), leading to Aβ formation. Evidence for this hypothesis comes from mutations that cause hereditary AD in humans and in animal models of AD [14]. Aβ is produced by the sequential cleavage of AβPP by β-secretase and γ-secretase yielding a 38–43 amino acid protein [2]. The most prevalent forms of Aβ are Aβ40 and Aβ42, of which Aβ42 is known to be more toxic. Aβ forms soluble aggregates (oligomers and protofibrils) as well as insoluble fibrils that comprise the amyloid plaques [15]. Current thought is that oligomeric Aβ is responsible for the initiation of synaptic loss in AD [14,16]. Aβ oligomers can accumulate in subcellular organelles and can induce synaptic degeneration and overt toxicity in neurons [17–21]. The role of mitochondria in oligomeric Aβ-induction of synaptic degeneration is currently an area of intense research [19,22–26].

Correlated changes in synaptic function and mitochondrial function occur as early events in AD [21,27]. Several lines of evidence demonstrate this point. First, Aβ is known to associate with mitochondrial membranes in its monomeric and oligomeric forms [28–33]. Additionally, Aβ interacts with mitochondrial proteins Drp1 [19], ABAD [34] and cyclophilin D [35]. Oligomeric Aβ is known to decrease ATP production and induce free radical production [36]. Finally, mitochondrial transport, fission and fusion are all disrupted by oligomeric Aβ [19,22–26]. It has therefore been proposed that oligomeric Aβ-induced mitochondrial deficiencies precede and contribute to synaptic degeneration and loss in AD [21,27,36].

3. Mitochondrial Function Is Tightly Coupled to Synaptic Activity

Mitochondria play several key roles in synaptic maintenance. The dynamic mitochondrial functions of ATP generation, Ca2+ regulation, and modulation of caspase activity are all essential for neuronal viability. In the case of ATP generation, it has long been recognized that neuronal activity can stimulate oxidative phosphorylation. One of the most thoroughly studied examples in this regard is the coupling of cytochrome c oxidase (COX) transcription to neural activity. Ca2+ regulation by synaptic
mitochondria has also been carefully studied, and mitochondrial control of neurite pruning is an emerging field that has gained recent attention. For these three reasons, synaptic mitochondria are critical for the proper functioning and viability of synapses and neurons overall. Deficiencies in any of these areas would be expected to lead to drastic reductions in neuronal function.

Since neurons are non-dividing cells, the ATP that neurons consume is entirely utilized for cellular function, not replication. Therefore it has been highly informative to create energy budgets for neurons based on theoretical calculations. The major cellular process that hydrolyses ATP is the maintenance and re-establishment of the ion gradient, which is essential for neuronal activity. It is estimated that this process consumes approximately half of the ATP within neurons with another 30% dedicated to synaptic transmission [37,38]. The energy for these functions is used mainly in synapses and distal regions of the cell, and relies heavily on mitochondrial oxidative phosphorylation for ATP generation. It has been widely observed that neurons exhibit poor survival in anaerobic conditions, illustrating the previous point. Moreover, the preferred energetic substrate for the tricarboxylic acid (TCA) cycle in glutamatergic neurons is thought to be lactate, which is produced by anaerobic metabolism in astrocytes and is secreted by neurons for uptake [38–40]. It is well known that local energetic demand and production are strongly correlated with neuronal activity, and importantly it is neuronal activity that is responsible for enhanced metabolic activity, not vice-versa [41]. A clear demonstration of neural activity inducing ATP production comes from the upregulation of COX in active neurons. As early as 1989, Wong-Riley and colleagues demonstrated the use of COX activity as a surrogate marker for neuronal activity in the occipital cortex [41]. Since then, this method has gained wide acceptance. Subsequently, detailed molecular dissection of this phenomenon showed that COX regulation involves coordinated bigenomic transcription of both mitochondrial and nuclear-encoded genes [42]. In short, it appears that neuronal activity leads to activation of the nuclear respiratory factors 1 and 2 (Nrf-1 and Nrf-2) as well as the coactivator PGC1α [43]. These transcription factors operate coordinately to upregulate 13 nuclear genes encoding 10 COX subunits and three transcription factors (Tfam, Tf1m, and Tf2m) responsible for upregulation of the remaining three COX subunits within mtDNA [44]. Therefore, a picture of the mechanism by which stimulation of ATP production follows neuronal activity is emerging. Nrf-1, Nrf-2 and PGC1α not only regulate transcription of COX, but other mitochondrial constituents as well [43,44]. In fact, these proteins (especially PGC1α) are often regarded as master regulators of mitochondrial biogenesis [43–47], and as such, a likely conclusion is that neuronal activity stimulates mitochondrial biogenesis per se. It is still unknown what molecular signals recruit re-localization of the newly synthesized constituents and presumably an entire organelle to distal regions of the cell in order to satisfy the highly local energy demand for neural functions.

Mitochondrial Ca²⁺ clearance is also essential for correct synaptic function and overall neuronal survival. Ca²⁺ buffering is especially critical in the pre-synaptic and post-synaptic compartments where Ca²⁺ concentrations may vary widely and must be tightly regulated. Neuronal mitochondria are crucial for the central role they play in intracellular Ca²⁺ homeostasis due to their direct buffering capacity and their ability to generate ATP which fuels other mechanisms of Ca²⁺ mobilization [48]. Mitochondrial Ca²⁺ buffering is currently thought to account for a large proportion of the post-synaptic Ca²⁺ clearance after neuronal firing [49–51] and to be responsible for influencing Ca²⁺-dependent processes, such as synaptic vesicle release [52–54]. Using fluorescent probes Rhodamine123 (for mitochondria) and Fura-3 (for calcium), Kann and colleagues found the Ca²⁺ concentration of mitochondria to correlate
with electrical activity in hippocampal slice cultures [49]. Further, Pivovarova et al. found that mitochondria quickly sequestered intracellular Ca\textsuperscript{2+} in CA3 neurons, but the endoplasmic reticulum responded more slowly in both uptake and release [51]. Therefore, the cooperative action of endoplasmic reticulum and mitochondria result in the finely tuned buffering of Ca\textsuperscript{2+} in neurons [55–57].

Recently, researchers found that neurite pruning is mediated largely by local caspase signaling [58–62] and that much of this signaling proceeds through mitochondrial control of the apoptotic machinery. The extrinsic pathway of apoptosis may contribute to neurite pruning during development [61]. However, the intrinsic pathway seems to be fundamentally required for the reduction in dendritic spines. This may provide the basis for long-term depression (LTD) of neurons [63–65] and the degeneration of synapses seen in AD. A role for caspase-3 in the formation of LTD has been suggested. Li et al. [66] used a combination of peptide inhibitors and knockout animals in hippocampal slice cultures to show that mitochondrial activation of caspase-3 and caspase-9 is necessary for the formation of LTD but not for long-term potentiation. They then extended this work to show that BAD and BAX proteins functioned upstream of caspase activation in LTD formation, in cultured hippocampal neurons and slices [67]. The involvement of mitochondria in AD-induced spine loss can be illustrated by focusing on AMPA-receptor degradation and coincident spine degeneration. AMPA-receptor surface expression was found to be decreased in cultures treated with Aβ, and this decrease was associated with spinal loss and decreased AMPA responsiveness [68,69]. Moreover, AβPP primary neurons exhibit decreased GluR1, AMPA receptor subunit, and expression [70]. D’Amelio and colleagues showed that in the Tg2576 mouse model of AD, mitochondria-mediated apaf-1 activation of caspase-3 leads to early loss of hippocampal dendritic spines, and that this activation also diminished post-synaptic AMPA receptors [60]. This neuritic simplification strongly correlated with behavioral abnormalities in AD mice that have been found long before the deposition of amyloid plaques [60]. In a study in which primary hippocampal neurons were exposed to Aβ oligomers, GluR1-immunopositive spines were rapidly lost (within 30 min) and mitochondria were implicated in protecting from the loss of AMPA receptors. The probability of an individual spine showing GluR1 immunoreactivity after treatment correlated strongly with the probability that a mitochondrion exists in close proximity to the spine [71].

Based on these studies, mitochondria appear to be central to proper regulation of AMPA receptor endocytosis and that a corresponding degeneration in spines and synapses is reliant on mitochondrial-mediated caspase activation [60,72]. Thus, the limited activation of caspases, which results in synaptic loss, may explain how behavioral deficits in AD may precede frank neuronal degeneration.

4. Mitochondria Are Highly Regulated in Neurons

The mitochondrial lifecycle in neurons involves biosynthesis, distribution, recycling, and autophagy (Figure 1). Mitochondrial biosynthesis is thought to occur largely in the neuronal soma, based on pioneering work in which mitochondrial DNA (mtDNA) synthesis was studied in PC12 cells [73]. In this work, researchers reported that the incorporation of BrdU into mtDNA occurred in a perinuclear pattern, with incorporation decreasing the further the mitochondria were from the nucleus. In a subsequent study, however, the same researchers decoupled the synthesis of mtDNA from transcription of mitochondrial substituents. They found that the putative nuclear gene product required
for mtDNA synthesis (*Polγ*) is transcribed in the absence of cellular mtDNA while the nuclear gene product for the mtDNA transcription factor *Tfam* is not [74]. More recently, researchers have found that protein synthesis occurs in the axons and dendrites of neurons [75–77], with mitochondrial proteins, in particular, being synthesized in axons [78,79].

**Figure 1.** Primary hippocampal neuron with mitochondria labeled by MitoDsRed2 and cytosol labeled by GFP. The figure illustrates the mitochondrial lifecycle, including biogenesis, mitochondrial transport, and synaptic localization and degradation. Because of neuronal architecture with long processes and high energetic demands at distal regions of the cell, mitochondrial distribution is critical to the survival of neurons. Disruptions in regulating several aspects of mitochondrial biology are known to lead to neurodegeneration.

**Maintaining mitochondrial balance within neurons**

Researchers also found that mtDNA replication occurs throughout the cell body of fibroblasts [80] and within axons that had been resected from the cell body [81]. In our own studies, we found that healthy neurons exhibited mtDNA replication mainly within the soma, but also to some extent within axons and dendrites [82]. Additionally, we found that a perinuclear localization of mitochondria was greater in neurons that had been treated with toxins, such as rotenone, hydrogen peroxide, and Aβ. Overall, it appears likely that mitochondrial biogenesis does, indeed, occur largely in the cell soma by virtue of the sheer abundance of protein synthesis machinery there, and to a lesser extent, it also occurs in axonal compartments.

Since newly synthesized mitochondria occur mainly in the cell soma, they must be transported to distal regions to function in ATP generation, Ca$^{2+}$ buffering, and LTD formation. Mitochondrial transport processes are illustrated in Figure 2. Detailing the molecular mechanisms of mitochondrial transport, especially within neurons, is an important and intensive area of study. Currently, many of the key players have been identified in this complex and highly regulated process; however, the exact regulatory mechanisms and even many of the context-specific on/off signals are as yet undescribed [83]. Both synaptic activity and active growth are known to signal mitochondrial motility, while syntaphilin and Ca$^{2+}$ are thought to provide stop signals.
Figure 2. An illustration showing the transport of mitochondria from cell body to nerve terminal. Mitochondria are transported along microtubules and are attached to molecular motors by Miro and Milton. These two proteins provide important points of regulation for mitochondrial transport and may prove to mediate the signals for mitochondrial distribution.

The direction of movement may be related to the polarization of the organelle; however, this has not been conclusively determined. Using the dye JC-1 to distinguish between polarized and depolarized mitochondria, Miller and Sheetz showed that polarized mitochondria tended to move anterograde, toward the distal synapses, while depolarized mitochondria tended to move retrograde [84]. However, in a more recent study using the mitochondrial dye TMRM, which may be a more reliable measure of mitochondrial potential, this pattern was not observed [85]. The transport machinery utilizes both kinesin and dynein motors, which operate along microtubules. Mitochondria are attached to the motors by two proteins miro and milton, which provide key points of regulation.

Decreased mitochondrial transport has been found in many diseases, including AD, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and Parkinson’s disease [86–88]. In fact, in AD, current evidence suggests that this decrease in transport is an early event in neurodegeneration that precedes axonal loss [25,89–91]. Hydrogen peroxide treatment was shown to inhibit both mitochondria and Golgi-derived vesicle transport along axons demonstrating that oxidative stress can directly influence transport phenomena [92]. Potential mechanisms involved in the interference of mitochondrial transport include direct interference with transport machinery, alterations in move, stop or directional signals, or alterations in mitochondrial fission and fusion.

5. Impaired Mitochondrial Dynamics in Alzheimer’s Disease Neurons

Mitochondrial dynamics is a process by which mitochondria divide and fuse in most eukaryotic cells. Mitochondrial shape and structure are maintained by equal and opposite forces: mitochondrial fission and mitochondrial fusion. In healthy cells, fission and fusion events balance equally, resulting in the maintenance of mitochondrial function. Mitochondria alter their shape and size to move from the cell body to the axons, dendrites, and synapses, and back to the cell body [36]. As described above, mitochondria are synthesized in the cell body and travel along the axons and dendrites to supply energy to nerve terminals for normal neural communication. After use, damaged mitochondria are
thought to be recycled by fusion with healthy mitochondria, intraorganelle exchange of proteins, lipids and DNA and subsequent fission (Figure 3).

**Figure 3.** Illustration showing mitochondrial dynamics in a healthy neuron. Mitochondrial fission and fusion are the means by which mitochondria are recycled. Dilution of damaged mitochondrial constituents occurs by this process thereby extending the lifespan of otherwise non-functional organelles. Oxidative stress within the cell is known to result in mitochondrial fragmentation which disrupts normal mitochondrial cycling.

Fission and fusion are controlled by evolutionary conserved, dynamin related large GTPases. Fission is regulated by the dynamin-related protein (Drp1) and mitochondrial fission 1 (Fis1), of which the latter is localized to the mitochondrial outer membrane [36]. When a mitochondrion signals to divide, Drp1, a cytosolic protein, translocates to the mitochondrial outer membrane and to initiate the process of fragmentation.

Mitochondrial fusion is controlled by three GTPase proteins: two proteins located in the outer mitochondrial membrane mitofusins 1 [Mfn1] and 2 [Mfn2]), and one protein located in the inner membrane localized protein (optic atrophy 1 [Opa1]). The C-terminal portion of Mfn1 mediates oligomerization between Mfn molecules of adjacent mitochondria and facilitates mitochondrial fusion.

Interestingly, direct links between mitochondrial fusion and transport are being uncovered in neurons. For example, Mfn2 was found to be required for mitochondrial transport [93]. Conversely, overexpression of the transport protein Miro was shown to increase mitochondrial fusion in cell lines [94,95].

Recent evidence from our lab [19,22,26] and others [23,24] suggests that impaired mitochondrial dynamics in AD neurons is present and furthermore may result from Aβ interaction with Drp1 and subsequent increased production of free radicals. In turn, this elevation of free radicals activates fission proteins Drp1 and Fis1 and cause excessive mitochondrial fragmentation, defective transport of mitochondria to synapses, low synaptic ATP and synaptic dysfunction in AD neurons [96,97].

6. Oxidative Stress in Mitochondria Is Associated with AD

The term *oxidative stress* is commonly offered to explain the balance between the production of oxidants and the endogenous antioxidant defenses in cells, including neurons. In general, cells undergo
apoptotic death when there is an imbalance between endogenous antioxidant enzymes and oxidants produced within the mitochondria.

Mitochondria-linked oxidative stress has been found to be a major factor associated with the development and progression of AD [27]. Further, increasing evidence suggests that free radical associated oxidative damage of lipids, nucleic acids, and proteins is extensive in the brains of AD patients [27,97,98]. The brain appears to be more vulnerable to oxidative stress compared to other organs in the body. Oxidative stress markers, such as 8-hydroxyguanosine and hemeoxygenase, have been localized to pathologic sites in the brains of AD patients [98].

7. Mitochondria-Targeted Antioxidants May Be Beneficial in AD

Initial clinical application of antioxidants to prevent or delay symptoms of AD has met with limited success. This underwhelming response may be due at least in part to the non-specific nature of antioxidant therapies. Up to now, there are literally dozens of completed or ongoing clinical trials using such antioxidants as vitamin E, epigallocatechin gallate (EGCG), resveratrol, curcumin, pramipexole, latrepirdine, ubiquinone, lipoic acid, idebenone, Ginkgo biloba, and N-acetylcysteine [99]. Many of the non-traditional antioxidants are known to modulate glutathione levels in brain, and this strategy has been proposed as a potential treatment in AD [100]. Unfortunately, only a handful of these trials have yielded positive results, with several showing a negative association between antioxidant supplementation and positive outcomes. Because of challenges including blood brain barrier penetration, use of late stage AD patients, and other aspects of the trial design, it has been proposed that generalized antioxidants have limited potential compared to more targeted approaches [96].

Because oxidative damage in mitochondria is thought to be a driving force in the dysfunction of mitochondria, investigators have begun to examine the efficacy of antioxidant therapies specifically targeted to mitochondria. Several mitochondria-targeted antioxidants have been developed in this regard and are currently undergoing preclinical testing. Candidate molecules including MitoQ, MitoVitE, MitoPBN, MitoPeroxidase, glutathione choline esters, latripirdine and Szeto-Schiller (SS) peptides, have been developed and the potential use of these molecules to combat neurodegenerative disease has been previously detailed [27,97,101–103]. One of the most promising mitochondria-targeted antioxidants from this category is SS31 [27,96–98].

SS31 was developed as a part of a series of SS peptides that were synthesized and characterized as opioid agonists [104,105]. Soon thereafter, it was discovered that both SS02 (Dmt-D-Arg-Phe-Lys-NH2; Dmt represents 2',6'-dimethyltyrosine) and SS31 (D-Arg-Dmt-Lys-Phe-NH2) exhibited mitochondrial accumulation as well as in vitro inhibition of lipid peroxidation and H2O2 scavenging [106]. Furthermore, these mitochondria-targeted antioxidant molecules were found to protect from Ca2+-induced mitochondrial depolarization, the swelling and release of cytochrome c in isolated organelles, and ischemia reperfusion injury in guinea pig heart [106]. SS31 was then evaluated in models of islet cell transplantation [107], myocardial infarction [108], brain ischemia reperfusion [109], and ALS [110]. Strikingly, SS31 was found to be beneficial in all of these conditions.

Based on the neuroprotection capacity of SS31, the Reddy lab has evaluated SS31 in models of AD, including Aβ-treated N2a neuroblastoma cells, primary neurons from Tg2576 mice and aging Tg2576 mice. In N2a neuroblastoma cells treated with Aβ25-35, we observed a broad range of effects on
mitochondria, suggesting dysfunction and increased oxidative stress [26]. First, mitochondrial fission genes and proteins were found to be upregulated, while fusion genes and proteins were down-regulated. There was also an accumulation of small, apparently fragmented, mitochondria within the cell body. Furthermore, Aβ treatment was associated with increased H2O2 production, along with decreased COX activity and ATP. Treating N2a cells with SS31 in combination with Aβ provided at least partial rescue in all of these parameters, compared to Aβ alone. SS31 treatment alone was associated with increased expression of mitochondrial fission and fusion genes and proteins, decreased H2O2 production, increased COX activity, and increased ATP levels. These findings suggest that a rescue effect may be conferred by SS31. Our lab also evaluated the efficacy of SS31 in primary neurons from Tg2576 mice. These neurons are known to be deficient in synaptic markers and to exhibit dendritic simplification due to excreted Aβ and intracellular accumulation of oligomeric Aβ [111–113]. We found that in addition to synaptic loss, aged Tg2576 neurons have increased numbers of rounded somatic mitochondria and concurrent loss of dendritic mitochondria, reminiscent of cells that have been treated with Aβ [22]. This mitochondrial alteration is coincident with an intracellular accumulation of oligomeric Aβ [22] as well as dendritic simplification [26], and precedes overt neuronal degeneration. These processes were further associated with increased mitochondrial fission, as evidenced by gene expression and protein levels of mitochondrial dynamics genes, as well a pronounced decrease in anterograde mitochondrial trafficking. Treatment with SS31 was able to reverse both the trafficking deficit and the occurrence of excess mitochondrial fission.

Since trafficking and dynamics are highly interrelated processes, it is not surprising that we found coincident reversal of both endpoints with the addition of SS31. If we are to accept the hypothesis that mitochondrial health is a determinant for anterograde transport (as suggested in [84]), then the mechanistic link between antioxidant therapy and correct mitochondrial distribution would be the reversal of ROS-mediated damage within the organelle, preventing depolarization. This prevention of ROS-induced depolarization would allow anterograde transport of mitochondria to proceed as normal, resulting in an efficient repopulation of spent mitochondria in the distal regions of the cell. In light of our recent study showing aberrant interactions between Drp1 and Aβ, it is likely that the induction of mitochondrial fission also plays a role in creating an abnormal distribution of mitochondria in Tg2576 neurons [114]. A positive effect of pharmacologically targeting Drp1 has been demonstrated in a cell model of Parkinson’s disease where mitochondrial division inhibitor-1 was shown to improve cell survival after 6-hydroxydopamine insult [115]. Furthermore, mito-Q treatment in the same model prevented Drp1 dependent fission and subsequent cell death [116]. Clarification about the mechanism by which Aβ, Drp1, and ROS interact may provide further drug targets for therapeutic intervention in AD.

8. Conclusions and Future Directions

Recent developments in AD research revealed that aging- and Aβ-induced mitochondrial abnormalities and synaptic degeneration are early events in AD pathogenesis. More specifically, Aβ-induced abnormal mitochondrial dynamics (increased fission and decreased fusion) is a critical factor that is responsible for mitochondrial structural and functional changes in AD neurons. Research utilizing primary neuronal cultures from AβPP transgenic mice also revealed defective axonal
transport of mitochondria, abnormal mitochondrial distribution, reduced functionally active mitochondria at synapses, and oligomeric Aβ accumulation at synapses. These findings further suggest that Aβ is toxic to mitochondria and synapses in AD neurons.

There is urgent need to develop molecules that reduce Aβ-induced mitochondrial and synaptic toxicities, and also to develop molecules that remove/sequester Aβ from AD neurons. There is significant progress in the development of mitochondria-targeted molecules, including MitoQ and also cell-permeable small peptides, such as SS31. These mitochondria-targeted molecules have been tested by several laboratories, using cell and animal models of neurodegenerative diseases and preliminary reports have been positive. More specifically, SS31 has been found to be protective against Aβ-induced mitochondrial and synaptic deficiencies in AD neurons and appears to be a promising molecule to test in humans with AD.

Acknowledgements

This research was supported by NIH grants AG028072 and RR000163, and the Alzheimer Association grant IIRG-09-92429. MJC is currently supported by the NCI under NIH award number T32CA106195.

References

1. Selkoe, D.J. Alzheimer’s disease: Genes, proteins, and therapy. *Physiol. Rev.* 2001, 81, 741–766.
2. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer’s disease. *Nat. Rev. Neurosci.* 2007, 8, 499–509.
3. Keller, J.N.; Pang, Z.; Geddes, J.W.; Begley, J.G.; Germeyer, A.; Waeg, G.; Mattson, M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. *J. Neurochem.* 1997, 69, 273–284.
4. Swerdlow, R.H.; Khan, S.M. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. *Med. Hypotheses* 2004, 63, 8–20.
5. Swerdlow, R.H.; Burns, J.M.; Khan, S.M. The Alzheimer’s disease mitochondrial cascade hypothesis. *J. Alzheimers Dis.* 2010, 20, S265–S279.
6. Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; et al. Mitochondrial abnormalities in Alzheimer’s disease. *J. Neurosci.* 2001, 21, 3017–3023.
7. Selkoe, D.J. Alzheimer’s disease is a synaptic failure. *Science* 2002, 298, 789–791.
8. Wyss-Coray, T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? *Nat. Med.* 2006, 12, 1005–1015.
9. Barsoum, M.J.; Yuan, H.; Gerencser, A.A.; Liot, G.; Kushnareva, Y.; Graber, S.; Kovacs, I.; Lee, W.D.; Waggoner, J.; Cui, J.; et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. *EMBO J.* 2006, 25, 3900–3911.
10. Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.S.; Mameczarz, J.; Holloway, H.W.; Giordano, T.; et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA 2005, 102, 17213–17218.

11. Bertoni-Freddari, C.; Fattoretti, P.; Casoli, T.; Meier-Ruge, W.; Ulrich, J. Morphological adaptive response of the synaptic junctional zones in the human dentate gyrus during aging and Alzheimer’s disease. Brain Res. 1990, 517, 69–75.

12. DeKosky, S.T.; Scheff, S.W.; Styren, S.D. Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration 1996, 5, 417–421.

13. Tampellini, D.; Gouras, G.K. Synapses, synaptic activity and intraneuronal abeta in Alzheimer’s disease. Front. Aging Neurosci. 2010, 2, 13.

14. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356.

15. Walsh, D.M.; Selkoe, D.J. A beta oligomers—A decade of discovery. J. Neurochem. 2007, 101, 1172–1184.

16. Klein, W.L.; Krafft, G.A.; Finch, C.E. Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001, 24, 219–224.

17. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95, 6448–6453.

18. Lacor, P.N.; Buniel, M.C.; Chang, L.; Fernandez, S.J.; Gong, Y.; Viola, K.L.; Lambert, M.P.; Velasco, P.T.; Bigio, E.H.; Finch, C.E.; et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24, 10191–10200.

19. Manczak, M.; Calkins, M.J.; Reddy, P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage. Hum. Mol. Genet. 2011, 20, 2495–2509.

20. Broersen, K.; Rousseau, F.; Schymkowitz, J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer’s disease: Oligomer size or conformation? Alzheimers Res. Ther. 2010, 2, 12.

21. Reddy, P.H.; Manczak, M.; Mao, P.; Calkins, M.J.; Reddy, A.P.; Shirendeb, U. Amyloid-beta and mitochondria in aging and Alzheimer’s disease: Implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010, 20, S499–S512.

22. Calkins, M.J.; Manczak, M.; Mao, P.; Shirendeb, U.; Reddy, P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 2011, 20, 4515–4529.

23. Wang, X.; Su, B.; Siedlak, S.L.; Moreira, P.I.; Fujioka, H.; Wang, Y.; Casadesus, G.; Zhu, X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. USA 2008, 105, 19318–19323.
24. Wang, X.; Su, B.; Lee, H.G.; Li, X.; Perry, G.; Smith, M.A.; Zhu, X. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. *J. Neurosci*. 2009, 29, 9090–9103.

25. Du, H.; Guo, L.; Yan, S.; Sosunov, A.A.; McKhann, G.M.; Yan, S.S. Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. *Proc. Natl. Acad. Sci. USA* 2010, 107, 18670–18675.

26. Manczak, M.; Mao, P.; Calkins, M.J.; Cornea, A.; Reddy, A.P.; Murphy, M.P.; Szeto, H.H.; Park, B.; Reddy, P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. *J. Alzheimers Dis.* 2010, 20, S609–S631.

27. Reddy, P.H.; Beal, M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. *Trends Mol. Med.* 2008, 14, 45–53.

28. Manczak, M.; Anekonda, T.S.; Henson, E.; Park, B.S.; Quinn, J.; Reddy, P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. *Hum. Mol. Genet.* 2006, 15, 1437–1449.

29. Devi, L.; Prabhu, B.M.; Galati, D.F.; Avadhani, N.G.; Anandatheerthavarada, H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. *J. Neurosci.* 2006, 26, 9057–9068.

30. Crouch, P.J.; Blake, R.; Duce, J.A.; Ciccotosto, G.D.; Li, Q.X.; Barnham, K.J.; Curtain, C.C.; Cherry, R.A.; Cappai, R.; Dyrrs, T.; et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. *J. Neurosci.* 2005, 25, 672–679.

31. Caspersen, C.; Wang, N.; Yao, J.; Sosunov, A.; Chen, X.; Lustbader, J.W.; Xu, H.W.; Stern, D.; McKhann, G.; Yan, S.D. Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. *FASEB J.* 2005, 19, 2040–2041.

32. Hansson Petersen, C.A.; Alikhani, N.; Behbahani, H.; Wiehager, B.; Pavlov, P.F.; Alafuzoff, I.; Leinonen, V.; Ito, A.; Winblad, B.; Glaser, E.; et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13145–13150.

33. Yao, J.; Irwin, R.W.; Zhao, L.; Nilsen, J.; Hamilton, R.T.; Brinton, R.D. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. *Proc. Natl. Acad. Sci. USA* 2009, 106, 14670–14675.

34. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. *Science* 2004, 304, 448–452.

35. Du, H.; Guo, L.; Fang, F.; Chen, D.; Sosunov, A.A.; McKhann, G.M.; Yan, Y.; Wang, C.; Zhang, H.; Molkentin, J.D.; et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. *Nat. Med.* 2008, 14, 1097–1105.

36. Reddy, P.H. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer’s disease. *Exp. Neurol.* 2009, 218, 286–292.

37. Attwell, D.; Laughlin, S.B. An energy budget for signaling in the grey matter of the brain. *J. Cereb. Blood Flow Metab.* 2001, 21, 1133–1145.
38. Ames, A., 3rd. CNS energy metabolism as related to function. *Brain Res. Brain Res. Rev.* 2000, 34, 42–68.
39. Pellerin, L. Food for thought: The importance of glucose and other energy substrates for sustaining brain function under varying levels of activity. *Diabetes Metab.* 2010, 36, S59–S63.
40. Pellerin, L.; Bouzier-Sore, A.K.; Aubert, A.; Serres, S.; Merle, M.; Costalat, R.; Magistretti, P.J. Activity-dependent regulation of energy metabolism by astrocytes: An update. *Glia* 2007, 55, 1251–1262.
41. Wong-Riley, M.T. Cytochrome oxidase: An endogenous metabolic marker for neuronal activity. *Trends Neurosci.* 1989, 12, 94–101.
42. Wong-Riley, M.T. Bigenomic regulation of cytochrome C oxidase in neurons and the tight coupling between neuronal activity and energy metabolism. *Adv. Exp. Med. Biol.* 2012, 748, 283–304.
43. Scarpulla, R.C. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. *Ann. NY Acad. Sci.* 2008, 1147, 321–334.
44. Kelly, D.P.; Scarpulla, R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. *Genes Dev.* 2004, 18, 357–368.
45. Scarpulla, R.C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim. Biophys. Acta* 2011, 1813, 1269–1278.
46. Fernandez-Marcos, P.J.; Auwerx, J. Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. *Am. J. Clin. Nutr.* 2011, 93, S884–S890.
47. Ventura-Clapier, R.; Garnier, A.; Veksler, V. Transcriptional control of mitochondrial biogenesis: The central role of PGC-1alpha. *Cardiovasc. Res.* 2008, 79, 208–217.
48. Kann, O.; Kovacs, R. Mitochondria and neuronal activity. *Am. J. Physiol. Cell Physiol.* 2007, 292, C641–C657.
49. Kann, O.; Schuchmann, S.; Buchheim, K.; Heinemann, U. Coupling of neuronal activity and mitochondrial metabolism as revealed by NAD(P)H fluorescence signals in organotypic hippocampal slice cultures of the rat. *Neuroscience* 2003, 119, 87–100.
50. Bindokas, V.P.; Lee, C.C.; Colmers, W.F.; Miller, R.J. Changes in mitochondrial function resulting from synaptic activity in the rat hippocampal slice. *J. Neurosci.* 1998, 18, 4570–4587.
51. Pivovarova, N.B.; Pozzo-Miller, L.D.; Hongpaisan, J.; Andrews, S.B. Correlated calcium uptake and release by mitochondria and endoplasmic reticulum of CA3 hippocampal dendrites after afferent synaptic stimulation. *J. Neurosci.* 2002, 22, 10653–10661.
52. David, G.; Barrett, E.F. Mitochondrial Ca\(^{2+}\) uptake prevents desynchronization of quantal release and minimizes depletion during repetitive stimulation of mouse motor nerve terminals. *J. Physiol.* 2003, 548, 425–438.
53. Garcia-Chacon, L.E.; Nguyen, K.T.; David, G.; Barrett, E.F. Extrusion of Ca\(^{2+}\) from mouse motor terminal mitochondria via a Na\(^+\)-Ca\(^{2+}\) exchanger increases post-tetanic evoked release. *J. Physiol.* 2006, 574, 663–675.
54. Medler, K.; Gleason, E.L. Mitochondrial Ca\(^{2+}\) buffering regulates synaptic transmission between retinal amacrine cells. *J. Neurophysiol.* 2002, 87, 1426–1439.
55. Calupca, M.A.; Prior, C.; Merriam, L.A.; Hendricks, G.M.; Parsons, R.L. Presynaptic function is altered in snake K⁺-depolarized motor nerve terminals containing compromised mitochondria. *J. Physiol.* 2001, 532, 217–227.

56. Scotti, A.L.; Chatton, J.Y.; Reuter, H. Roles of Na⁺-Ca²⁺ exchange and of mitochondria in the regulation of presynaptic Ca²⁺ and spontaneous glutamate release. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 1999, 354, 357–364.

57. Malli, R.; Graier, W.F. Mitochondrial Ca²⁺ channels: Great unknowns with important functions. *FEBS Lett.* 2010, 584, 1942–1947.

58. Ohsawa, S.; Hamada, S.; Kuida, K.; Yoshida, H.; Igaki, T.; Miura, M. Maturation of the olfactory sensory neurons by Apaf-1/caspase-9-mediated caspase activity. *Proc. Natl. Acad. Sci. USA* 2010, 107, 13366–13371.

59. Hyman, B.T.; Yuan, J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. *Nat. Rev. Neurosci.* 2012, 13, 395–406.

60. D’Amelio, M.; Cavallucci, V.; Middei, S.; Marchetti, C.; Pacioni, S.; Ferri, A.; Diamantini, A.; de Zio, D.; Carrara, P.; Battistini, L.; et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer’s disease. *Nat. Neurosci.* 2011, 14, 69–76.

61. Park, K.J.; Grosso, C.A.; Aubert, I.; Kaplan, D.R.; Miller, F.D. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. *Nat. Neurosci.* 2010, 13, 559–566.

62. Li, Z.; Sheng, M. Caspases in synaptic plasticity. *Mol. Brain* 2012, 5, 15.

63. Nagerl, U.V.; Eberhorn, N.; Cambridge, S.B.; Bonhoeffer, T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. *Neuron* 2004, 44, 759–767.

64. Zhou, Q.; Homma, K.J.; Poo, M.M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. *Neuron* 2004, 44, 749–757.

65. Okamoto, K.; Nagai, T.; Miyawaki, A.; Hayashi, Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. *Nat. Neurosci.* 2004, 7, 1104–1112.

66. Li, Z.; Jo, J.; Jia, J.M.; Lo, S.C.; Whitcomb, D.J.; Jiao, S.; Cho, K.; Sheng, M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. *Cell* 2010, 141, 859–871.

67. Jiao, S.; Li, Z. Nonapoptotic function of BAD and BAX in long-term depression of synaptic transmission. *Neuron* 2011, 70, 758–772.

68. Hsieh, H.; Boehm, J.; Sato, C.; Iwatsubo, T.; Tomita, T.; Sisodia, S.; Malinow, R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. *Neuron* 2006, 52, 831–843.

69. Ting, J.T.; Kelley, B.G.; Lambert, T.J.; Cook, D.G.; Sullivan, J.M. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. *Proc. Natl. Acad. Sci. USA* 2007, 104, 353–358.

70. Almeida, C.G.; Tampellini, D.; Takahashi, R.H.; Greengard, P.; Lin, M.T.; Snyder, E.M.; Gouras, G.K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. *Neurobiol. Dis.* 2005, 20, 187–198.
71. Rui, Y.; Gu, J.; Yu, K.; Hartzell, H.C.; Zheng, J.Q. Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: The mitochondrial contribution. *Mol. Brain* **2010**, *3*, 10.

72. Chan, S.L.; Griffin, W.S.; Mattson, M.P. Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. *J. Neurosci. Res.* **1999**, *57*, 315–323.

73. Davis, A.F.; Clayton, D.A. *In situ* localization of mitochondrial DNA replication in intact mammalian cells. *J. Cell Biol.* **1996**, *135*, 883–893.

74. Davis, A.F.; Ropp, P.A.; Clayton, D.A.; Copeland, W.C. Mitochondrial DNA polymerase gamma is expressed and translated in the absence of mitochondrial DNA maintenance and replication. *Nucleic Acids Res.* **1996**, *24*, 2753–2759.

75. Koenig, E.; Giuditta, A. Protein-synthesizing machinery in the axon compartment. *Neuroscience* **1999**, *89*, 5–15.

76. Alvarez, J.; Giuditta, A.; Koenig, E. Protein synthesis in axons and terminals: Significance for maintenance, plasticity and regulation of phenotype. With a critique of slow transport theory. *Prog. Neurobiol.* **2000**, *62*, 1–62.

77. Twiss, J.L.; van Minnen, J. New insights into neuronal regeneration: The role of axonal protein synthesis in pathfinding and axonal extension. *J. Neurotrauma* **2006**, *23*, 295–308.

78. Gioio, A.E.; Eyman, M.; Zhang, H.; Lavina, Z.S.; Giuditta, A.; Kaplan, B.B. Local synthesis of nuclear-encoded mitochondrial proteins in the presynaptic nerve terminal. *J. Neurosci. Res.* **2001**, *64*, 447–453.

79. Sotelo-Silveira, J.R.; Calliari, A.; Kun, A.; Koenig, E.; Sotelo, J.R. RNA trafficking in axons. *Traffic* **2006**, *7*, 508–515.

80. Magnusson, J.; Orth, M.; Lestienne, P.; Taanman, J.W. Replication of mitochondrial DNA occurs throughout the mitochondria of cultured human cells. *Exp. Cell Res.* **2003**, *289*, 133–142.

81. Amiri, M.; Hollenbeck, P.J. Mitochondrial biogenesis in the axons of vertebrate peripheral neurons. *Dev. Neurobiol.* **2008**, *68*, 1348–1361.

82. Calkins, M.J.; Reddy, P.H. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer’s disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. *Biochim. Biophys. Acta* **2011**, *1812*, 1182–1189.

83. Sheng, Z.H.; Cai, Q. Mitochondrial transport in neurons: Impact on synaptic homeostasis and neurodegeneration. *Nat. Rev. Neurosci.* **2012**, *13*, 77–93.

84. Miller, K.E.; Sheetz, M.P. Axonal mitochondrial transport and potential are correlated. *J. Cell Sci.* **2004**, *117*, 2791–2804.

85. Verburg, J.; Hollenbeck, P.J. Mitochondrial membrane potential in axons increases with local nerve growth factor or semaphorin signaling. *J. Neurosci.* **2008**, *28*, 8306–8315.

86. Schon, E.A.; Przedborski, S. Mitochondria: The next (neuro)generation. *Neuron* **2011**, *70*, 1033–1053.

87. Reddy, P.H.; Shirendeb, U.P. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. *Biochim. Biophys. Acta* **2012**, *1822*, 101–110.

88. Martin, L.J. Mitochondrial pathobiology in ALS. *J. Bioenerg. Biomembr.* **2011**, *43*, 569–579.
89. Calkins, M.J.; Reddy, P.H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons. *Biochim. Biophys. Acta* 2011, 1812, 507–513.

90. Wang, X.; Perry, G.; Smith, M.A.; Zhu, X. Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons. *Neurodegener. Dis.* 2010, 7, 56–59.

91. Rui, Y.; Tiwari, P.; Xie, Z.; Zheng, J.Q. Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. *J. Neurosci.* 2006, 26, 10480–10487.

92. Fang, C.; Bourdette, D.; Banker, G. Oxidative stress inhibits axonal transport: Implications for neurodegenerative diseases. *Mol. Neurodegener.* 2012, 7, 29.

93. Misko, A.; Jiang, S.; Wegrzewska, I.; Milbrandt, J.; Baloh, R.H. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. *J. Neurosci.* 2010, 30, 4232–4240.

94. Fransson, A.; Ruusala, A.; Aspenstrom, P. Atypical Rho GTPases have roles in mitochondrial homeostasis and apoptosis. *J. Biol. Chem.* 2003, 278, 6495–6502.

95. Saotome, M.; Safiulina, D.; Szabadkai, G.; Das, S.; Fransson, A.; Aspenstrom, P.; Rizzuto, R.; Hajnoczky, G. Bidirectional Ca^{2+}-dependent control of mitochondrial dynamics by the Miro GTPase. *Proc. Natl. Acad. Sci. USA* 2008, 105, 20728–20733.

96. Reddy, P.H.; Tripathi, R.; Troung, Q.; Tirumala, K.; Reddy, T.P.; Anekonda, V.; Shirendeb, U.P.; Calkins, M.J.; Reddy, A.P.; Mao, P.; et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. *Biochim. Biophys. Acta* 2012, 1822, 639–649.

97. Reddy, P.H. Mitochondrial oxidative damage in aging and Alzheimer’s disease: Implications for mitochondrially targeted antioxidant therapeutics. *J. Biomed. Biotechnol.* 2006, 2006, 31372.

98. Chaturvedi, R.K.; Beal, M.F. Mitochondrial approaches for neuroprotection. *Ann. NY Acad. Sci.* 2008, 1147, 395–412.

99. Mecocci, P.; Polidori, M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. *Biochim. Biophys. Acta* 2012, 1822, 631–638.

100. Pocernich, C.B.; Butterfield, D.A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. *Biochim. Biophys. Acta* 2012, 1822, 625–630.

101. Murphy, M.P.; Smith, R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. *Annu. Rev. Pharmacol. Toxicol.* 2007, 47, 629–656.

102. Szeto, H.H. Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents. *AAPS J.* 2006, 8, E521–E531.

103. Sheu, S.S.; Nauduri, D.; Anders, M.W. Targeting antioxidants to mitochondria: A new therapeutic direction. *Biochim. Biophys. Acta* 2006, 1762, 256–265.

104. Schiller, P.W.; Nguyen, T.M.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N.N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. *Eur. J. Med. Chem.* 2000, 35, 895–901.

105. Zhao, G.M.; Qian, X.; Schiller, P.W.; Szeto, H.H. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. *J. Pharmacol. Exp. Ther.* 2003, 307, 947–954.
106. Zhao, K.; Zhao, G.M.; Wu, D.; Soong, Y.; Birk, A.V.; Schiller, P.W.; Szeto, H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. *J. Biol. Chem.* 2004, 279, 34682–34690.

107. Thomas, D.A.; Stauffer, C.; Zhao, K.; Yang, H.; Sharma, V.K.; Szeto, H.H.; Suthanthiran, M. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. *J. Am. Soc. Nephrol.* 2007, 18, 213–222.

108. Cho, J.; Won, K.; Wu, D.; Soong, Y.; Liu, S.; Szeto, H.H.; Hong, M.K. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. *Coron. Artery Dis.* 2007, 18, 215–220.

109. Cho, S.; Szeto, H.H.; Kim, E.; Kim, H.; Tolhurst, A.T.; Pinto, J.T. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. *J. Biol. Chem.* 2007, 282, 4634–4642.

110. Petri, S.; Kiaei, M.; Damiano, M.; Hiller, A.; Wille, E.; Manfredi, G.; Calingasan, N.Y.; Szeto, H.H.; Beal, M.F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. *J. Neurochem.* 2006, 98, 1141–1148.

111. Takahashi, R.H.; Almeida, C.G.; Kearney, P.F.; Yu, F.; Lin, M.T.; Milner, T.A.; Gouras, G.K. Oligomerization of Alzheimer’s beta-amyloid within processes and synapses of cultured neurons and brain. *J. Neurosci.* 2004, 24, 3592–3599.

112. Wu, H.Y.; Hudry, E.; Hashimoto, T.; Kuchibhotla, K.; Rozkalne, A.; Fan, Z.; Spires-Jones, T.; Xie, H.; Arbel-Ornath, M.; Grosskreutz, C.L.; *et al.* Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. *J. Neurosci.* 2010, 30, 2636–2649.

113. Wu, H.Y.; Hudry, E.; Hashimoto, T.; Uemura, K.; Fan, Z.Y.; Berezovska, O.; Grosskreutz, C.L.; Bacskai, B.J.; Hyman, B.T. Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid-beta revealed by a novel fluorescence resonance energy transfer assay. *J. Neurosci.* 2012, 32, 5298–5309.

114. Manczak, M.; Reddy, P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. *Hum. Mol. Genet.* 2012, 21, 2538–2547.

115. Galindo, M.F.; Solesio, M.E.; Atienza-Aroca, S.; Zamora, M.J.; Jordan Bueso, J. Mitochondrial dynamics and mitophagy in the 6-hydroxydopamine preclinical model of Parkinson’s disease. *Parkinsons Dis.* 2012, 2012, 131058.

116. Solesio, M.E.; Prime, T.A.; Logan, A.; Murphy, M.P.; Del Mar Arroyo-Jimenez, M.; Jordan, J.; Galindo, M.F. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson’s disease. *Biochim. Biophys. Acta* 2012, in press.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).